Introduction of endocrine therapy for breast cancer, one indication
(A) any ERC and the PRC or receptor unknown breast cancer patients, regardless of age, menopausal status, tumor size, axillary lymph node positive, endocrine therapy can be considered;
(B) receptor-negative patients with endocrine adjuvant therapy is not recommended;
(C), although receptor-positive, the following conditions may also be considered without endocrine therapy: premenopausal, young patients, tumor <1cm, No, to the deprivation of estrogen, when concerns about adverse reactions; postmenopausal patients with venous a history of thrombosis.
(D) endocrine therapy with chemotherapy, the choice of: receptor-positive, postmenopausal, No, or Nr, no vital organs by the offender, endocrine therapy can be used alone, such as the recurrence of progress, then consider using or combined with chemotherapy; The indications of receptor-positive patients with chemotherapy, especially in premenopausal patients, chemotherapy and hormone therapy should be considered the sequential use.
Breast cancer endocrine therapy introduced two rescue treatment of metastatic breast cancer endocrine
The treatment of advanced metastatic breast cancer more difficult, the main purpose of treatment is to relieve symptoms and prolong quality survival. Endocrine drugs easy to use and effective, and toxicity, it is particularly suitable for the treatment of advanced metastatic breast cancer. Its onset generally slower, often taking 2-3 months to see the tumor shrink, therefore, no significant progress if the tumor is necessary to at least 16 weeks after the evaluation of drug efficacy.
1. Premenopausal patients can choose ZoladexC Nuolei De 3.6mg injected subcutaneously, every 28 days, goserelinC / without TAM or anti-aromatase agents.
2. Postmenopausal patients can choose the first anti-aromatase agents.
3. For patients of all ages, if the initial line of endocrine therapy can be used without TAM and progesterone.
Breast cancer endocrine therapy introduction, three endocrine therapy options
The treatment of tamoxifen as the preferred treatment of postmenopausal patients can also choose selective aromatase inhibitors (anastrozole lag to music lag.) Tamoxifen, an aromatase inhibitor subsequent failure of endocrine therapy.